Diagnostic Approach for Amoebiasis

Clinical Recognition

In patients with gastrointestinal symptoms and travel to endemic areas, suspect amoebiasis when severe abdominal pain and bloody stools occur with minimal or absent fever, which distinguishes it from bacterial dysentery, according to the American College of Gastroenterology 1
Fever is notably uncommon or low-grade, present in only 8% of cases, contrasting sharply with bacterial causes where fever is expected, as noted by the Centers for Disease Control and Prevention 1
Severe cramping abdominal pain is prominent in patients with amoebiasis, as reported by the World Health Organization 1
Bloody diarrhea occurs in less than 15% of cases, but when present, is highly suggestive of invasive disease, according to the Infectious Diseases Society of America 1
Persistent or chronic diarrhea lasting ≥14 days is characteristic of amoebiasis, as stated by the American Gastroenterological Association 1
Fecal leukocytes are present in only 28% of cases, much lower than bacterial dysentery, as noted by the European Society of Clinical Microbiology and Infectious Diseases 1

Stool microscopy and culture should be performed in patients with relevant travel history presenting with acute colitis, as recommended by the British Society of Gastroenterology 3
Microscopic examination should ideally be performed within 15-30 minutes of stool passage to identify motile trophozoites, according to the World Health Organization 1
Fecal microscopy is usually negative in patients with amebic liver abscess, as reported by the Journal of Infection 4
Serology (indirect hemagglutination) has >92% sensitivity at presentation for amebic liver abscess and should be performed in all suspected cases, as recommended by the Infectious Diseases Society of America 4

Empirical therapy with tinidazole or metronidazole should be started in patients with suggestive history, epidemiology, and clinical presentation, as recommended by the Centers for Disease Control and Prevention 4
Tinidazole 2 g once daily for 3 days provides 96.5% cure rates, according to the Journal of Infection 4
Metronidazole 500 mg three times daily orally for 7-10 days results in >90% cure, as reported by the World Health Organization 4
Most patients respond within 72-96 hours, and if symptoms persist after 4 days of treatment, consider diagnostic uncertainty or complications, as noted by the American College of Gastroenterology 4

Once treatment with tinidazole or metronidazole is complete, all patients should receive a luminal amoebicide to reduce relapse risk, as recommended by the Infectious Diseases Society of America 4
Diloxanide furoate 500 mg orally three times daily or Paromomycin 30 mg/kg/day can be used as a luminal amoebicide, according to the Centers for Disease Control and Prevention 4